Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings

BACKGROUND: The incidence of acquired rifampicin resistance (RIF-ADR; RR) during first-line treatment varies. OBJECTIVES: Compare clinically significant RIF-ADR versus primary and reinfection RR, between regimens (daily versus no rifampicin in the continuation phase; daily versus intermittent rifamp...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Deun, Armand, Bola, Valentin, Lebeke, Rossin, Kaswa, Michel, Hossain, Mohamed Anwar, Gumusboga, Mourad, Torrea, Gabriela, De Jong, Bouke Catharine, Rigouts, Leen, Decroo, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994197/
https://www.ncbi.nlm.nih.gov/pubmed/35415609
http://dx.doi.org/10.1093/jacamr/dlac037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994197/
https://www.ncbi.nlm.nih.gov/pubmed/35415609
http://dx.doi.org/10.1093/jacamr/dlac037

Ejemplares similares